The securities of Imagion Biosystems Limited (‘IBX’) will be placed in trading halt at the request of IBX, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 17 September 2018 or when the announcement is released to the market.
Read the trading halt announcement.
Imagion Biosystems Delivers Major Milestone — IND Application Lodged with U.S. FDA for Phase 2 Trial of MagSense® HER2 Imaging Agent
January 31, 2026
Imagion Biosystems Hits Major Milestone, Submits IND Application to U.S. FDA for Phase 2 Trial of MagSense® HER2 Imaging Agent Key Highlights: Imagion Biosystems has